Akebia Therapeutics, Inc. (FRA:AX9)
Germany flag Germany · Delayed Price · Currency is EUR
1.184
+0.004 (0.34%)
At close: Jan 30, 2026

Akebia Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-15.91-69.41-51.93-94.23-282.02-384.84
Depreciation & Amortization
14.4941.741.8537.737.9734.69
Loss (Gain) From Sale of Assets
-0.17-----
Asset Writedown & Restructuring Costs
--0.788.77-114.43
Loss (Gain) From Sale of Investments
-----0.02-0.05
Stock-Based Compensation
9.787.789.3217.8522.7424.46
Provision & Write-off of Bad Debts
2.260.88----
Other Operating Activities
30.5718.07-2.68-41.873.98113.78
Change in Accounts Receivable
-36.314.050.9911.3-24.0311.67
Change in Inventory
-14.2-28.4-2.5419.09-24.956.16
Change in Accounts Payable
-4.94-1.36-5.241.5-11.743.68
Change in Unearned Revenue
3.88--3.744.651.82-32.39
Change in Other Net Operating Assets
42.95-13.96-10.2-37.98-46.72-1.97
Operating Cash Flow
32.4-40.66-23.38-73.15-252.97-110.39
Capital Expenditures
-0.22-0.03--0.11-0.06-0.32
Investment in Securities
----40-39.69
Investing Cash Flow
-0.05-0.03--0.1139.94-40
Long-Term Debt Issued
-45---19.98
Long-Term Debt Repaid
--37.1-32-33--
Net Debt Issued (Repaid)
9.547.9-32-33-19.98
Issuance of Common Stock
90.6243.036.797.688.95211.75
Other Financing Activities
-0.06-1.27-4044.78-
Financing Cash Flow
100.149.66-25.2114.6133.73231.72
Net Cash Flow
132.458.97-48.59-58.67-79.2981.33
Free Cash Flow
32.17-40.69-23.38-73.27-253.02-110.71
Free Cash Flow Margin
14.29%-25.40%-12.02%-25.05%-119.55%-37.57%
Free Cash Flow Per Share
0.13-0.19-0.13-0.40-1.52-0.80
Cash Interest Paid
5.045.046.066.769.637.84
Levered Free Cash Flow
50.7117.8322.11-15.3-136.04-17.99
Unlevered Free Cash Flow
67.129.225.88-5.5-123.53-12.42
Change in Working Capital
-8.63-39.68-20.73-1.44-105.61-12.86
Source: S&P Global Market Intelligence. Standard template. Financial Sources.